In contrast, the 2-marker panel correctly classified 17 of 18 before HCC treatment patients and all 36 healthy controls, with an AUC of 0.981 and 2% error rate, indicating that the 2-marker panel had improved discriminatory power compared with the AFP model. The gene discussed is AFP; the disease is hepatocellular carcinoma.